These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

274 related items for PubMed ID: 16334147

  • 1. Very early detection of response to imatinib mesylate therapy of gastrointestinal stromal tumours using 18fluoro-deoxyglucose-positron emission tomography.
    Heinicke T, Wardelmann E, Sauerbruch T, Tschampa HJ, Glasmacher A, Palmedo H.
    Anticancer Res; 2005; 25(6C):4591-4. PubMed ID: 16334147
    [Abstract] [Full Text] [Related]

  • 2. [18F-FDG PET/CT in response evaluation of gastrointestinal stromal tumours treated with imatinib].
    Banzo I, Quirce R, Martínez-Rodríguez I, Jiménez-Bonilla JF, Sainz-Esteban A, Barragán J, Portilla-Quattrociocchi H, Carril JM.
    Rev Esp Med Nucl; 2008; 27(3):168-75. PubMed ID: 18570858
    [Abstract] [Full Text] [Related]

  • 3. Early prediction of response to sunitinib after imatinib failure by 18F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor.
    Prior JO, Montemurro M, Orcurto MV, Michielin O, Luthi F, Benhattar J, Guillou L, Elsig V, Stupp R, Delaloye AB, Leyvraz S.
    J Clin Oncol; 2009 Jan 20; 27(3):439-45. PubMed ID: 19064982
    [Abstract] [Full Text] [Related]

  • 4. Gastrointestinal stromal tumours: correlation of F-FDG gamma camera-based coincidence positron emission tomography with CT for the assessment of treatment response--an AGITG study.
    Goldstein D, Tan BS, Rossleigh M, Haindl W, Walker B, Dixon J.
    Oncology; 2005 Jan 20; 69(4):326-32. PubMed ID: 16293972
    [Abstract] [Full Text] [Related]

  • 5. Highlighting the role of FDG PET scan in early response assessment of gastrointestinal stromal tumor treated with imatinib mesylate.
    Abhyankar SA, Nair N.
    Clin Nucl Med; 2008 Mar 20; 33(3):213-4. PubMed ID: 18287851
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Early response assessment in gastrointestinal stromal tumors with FDG PET scan 24 hours after a single dose of imatinib.
    Shinto A, Nair N, Dutt A, Baghel NS.
    Clin Nucl Med; 2008 Jul 20; 33(7):486-7. PubMed ID: 18580237
    [Abstract] [Full Text] [Related]

  • 9. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria.
    Choi H, Charnsangavej C, Faria SC, Macapinlac HA, Burgess MA, Patel SR, Chen LL, Podoloff DA, Benjamin RS.
    J Clin Oncol; 2007 May 01; 25(13):1753-9. PubMed ID: 17470865
    [Abstract] [Full Text] [Related]

  • 10. The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors.
    Gayed I, Vu T, Iyer R, Johnson M, Macapinlac H, Swanston N, Podoloff D.
    J Nucl Med; 2004 Jan 01; 45(1):17-21. PubMed ID: 14734662
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [Early response to treatment with Glivec detected with 18F-FDG PET in a patient with gastrointestinal stromal tumor].
    Delgado Bolton RC, Ortega Candil A, Pérez Castejón MJ, Garcerant M, Cabrera Martín MN, Lapeña Gutiérrez L, Carreras Delgado JL.
    Rev Esp Med Nucl; 2008 Jan 01; 27(2):112-7. PubMed ID: 18367049
    [Abstract] [Full Text] [Related]

  • 14. Patterns of extension of gastrointestinal stromal tumors (GIST) treated with imatinib (Gleevec®) by 18F-FDG PET/CT.
    Valls-Ferrusola E, García-Garzón JR, Ponce-López A, Soler-Peter M, Fuertes-Cabero S, Moragas-Solanes M, Riera-Gil E, Carrió-Gasset I, Lomeña-Caballero F.
    Rev Esp Enferm Dig; 2012 Jul 01; 104(7):360-6. PubMed ID: 22849497
    [Abstract] [Full Text] [Related]

  • 15. [Utility of FDG-PET for early evaluation of efficiency of imatinib mesylate (Glivec) in the treatment of gastrointestinal stromal tumors].
    García-González J, Sánchez Salmón A, Areses Manrique C, León Mateos L, Barandela Salgado J, López López R.
    Rev Esp Med Nucl; 2007 Jul 01; 26(2):100-2. PubMed ID: 17386236
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings.
    Choi H, Charnsangavej C, de Castro Faria S, Tamm EP, Benjamin RS, Johnson MM, Macapinlac HA, Podoloff DA.
    AJR Am J Roentgenol; 2004 Dec 01; 183(6):1619-28. PubMed ID: 15547201
    [Abstract] [Full Text] [Related]

  • 19. An in vivo tumor model exploiting metabolic response as a biomarker for targeted drug development.
    Cullinane C, Dorow DS, Kansara M, Conus N, Binns D, Hicks RJ, Ashman LK, McArthur GA, Thomas DM.
    Cancer Res; 2005 Nov 01; 65(21):9633-6. PubMed ID: 16266981
    [Abstract] [Full Text] [Related]

  • 20. Response evaluation of gastrointestinal stromal tumors.
    Choi H.
    Oncologist; 2008 Nov 01; 13 Suppl 2():4-7. PubMed ID: 18434631
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.